Listeria meningitis complicating infliximab treatment for Crohn's disease (Q36171112)

12 August 2017

0 references

Listeria meningitis complicating infliximab treatment for Crohn's disease (English)

1 reference

12 August 2017

0 references

1 reference

1 reference

Geoffrey Williams

1

1 reference

12 August 2017

Asad A Khan

series ordinal

2

1 reference

12 August 2017

Franzjosef Schweiger

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Canadian Journal of Infectious Diseases & Medical Microbiology

12 August 2017

1 reference

12 August 2017

16

1 reference

12 August 2017

5

1 reference

12 August 2017

289-292

1 reference

Creative Commons Attribution 4.0 International

12 August 2017

start time

1 January 2005

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Anti-cytokine therapeutics and infections

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Comparison of host resistance to primary and secondary Listeria monocytogenes infections in mice by intranasal and intravenous routes

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Adaptive immunity against Listeria monocytogenes in the absence of type I tumor necrosis factor receptor p55

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Immunity to Listeria infection

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Does administration of infliximab increase susceptibility to listeriosis?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Listeria meningitis associated with infliximab.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Meningitis due to Listeria monocytogenes as a complication of infliximab therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2095044

Listeria meningitis after treatment with infliximab

23 September 2018

1 reference

12 December 2020

Complications of infliximab therapy in children and adolescents affected by Crohn's disease

1 reference

12 December 2020

Reactivation of histoplasmosis after treatment with infliximab

1 reference

12 December 2020

Pneumocystis carinii pneumonia following a second infusion of infliximab

1 reference

12 December 2020

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

1 reference

12 December 2020

Identifiers

DOI

10.1155/2005/814698

1 reference

12 August 2017

1 reference

12 August 2017

1 reference